RESUMO
Clinical freedom should enable a physician to decide in a free and unbiased manner which is the most appropriate therapy to use for a particular patient. In order to implement the four aims of the German Haemophilia Society an average of 4-4.5 units of Factor VIII per capita of the general population per year is needed. At present European countries do not produce this amount, but to reduce the consumption of F VIII in therapy lowers treatment levels. Until plasma collection services in Europe can be expanded it is necessary that the additional, imported, sources of plasma are available, otherwise clinical freedom will be curtailed.
Assuntos
Fator VIII/provisão & distribuição , Hemofilia A/terapia , Autonomia Profissional , Adulto , Proteínas Sanguíneas/provisão & distribuição , Criança , Comércio , União Europeia , Fator VIII/efeitos adversos , Fator VIII/economia , Fator VIII/isolamento & purificação , Alemanha , Infecções por HIV/prevenção & controle , Infecções por HIV/transmissão , Política de Saúde , Humanos , SegurançaRESUMO
In many countries we could note the dramatic developments in regard to financial assistance of HIV-infected haemophiliacs and their families since we distributed the first overview on this to all World Federation of Hemophilia member countries. As a result of the untiring efforts of the National Haemophilia Societies, infected persons and their families receive essential assistance in 15 member countries. It is hoped that this development will sway more and more member countries to consider demands for financial support and provide them with the arguments to succeed.